A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

doi:10.1016/S1470-2045(18)30413-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

The Lancet. Oncology - 1 Sept 2018

Sun Roger, Limkin Elaine Johanna, Vakalopoulou Maria, Dercle Laurent, Champiat Stéphane, Han Shan Rong, Verlingue Loïc, Brandao David, Lancia Andrea, Ammari Samy, Hollebecque Antoine, Scoazec Jean-Yves, Marabelle Aurélien, Massard Christophe, Soria Jean-Charles, Robert Charlotte, Paragios Nikos, Deutsch Eric, Ferté Charles

Abstract excerpt

BACKGROUND: Because responses of patients with cancer to immunotherapy can vary in success, innovative predictors of response to treatment are urgently needed to improve treatment outcomes. We aimed to develop and independently validate a radiomics-based biomarker of tumour-infiltrating CD8 cells in patients included in phase 1 trials of anti-programmed cell death protein (PD)-1 or anti-programmed cell death...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to CD8-Positive T-Lymphocytes

Share to Lymphocytes, Tumor-Infiltrating

Share to Molecular Imaging

Share to Programmed Cell Death 1 Receptor

Share to RNA, Neoplasm

Share to Tomography, X-Ray Computed

Source

Open in PubMed

Identifiers

PMID: 30120041
DOI: 10.1016/S1470-2045(18)30413-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.PMID 30120041Read ↗

Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.Semantic proximity Read ↗

Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy responseSemantic proximity Read ↗

Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinomaSemantic proximity Read ↗

Predicting cell invasion in breast tumor microenvironment from radiological imaging phenotypes.Semantic proximity Read ↗

A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLCSemantic proximity Read ↗

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.Semantic proximity Read ↗

Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.Semantic proximity Read ↗

Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapySemantic proximity Read ↗

Predicting Cell Line Invasion in Breast Tumor Microenvironment from Radiological Imaging PhenotypesSemantic proximity Read ↗

Radiomics biomarkers are associated with survival in patients with Oesophageal AdenocarcinomaSemantic proximity Read ↗

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trialsSemantic proximity Read ↗

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.